Osivax Receives Over USD 1.5M Grant from NIAID to Advance Development of Broad-Spectrum Influenza Vaccine Candidate, OVX836

Osivax  Receives Over USD 1.5M Grant from NIAID to Advance Development of Broad-Spectrum Influenza Vaccine Candidate, OVX836 Grant to support preclinical evaluation of OVX836 in providing protection against pandemic influenza strains  OVX836 has already been evaluated in several Phase 2 clinical trials against seasonal influenza with initial signals of broad-spectrum protection Lyon, France – December 5, 2023 …

9th ESWI 2023

Valencia – PostersDelphine Guyon-Gellin, Chief Business Development Officer of Osivax, to provide a clinical update on OVX836 as part of a poster entitled « Co-Administration of OVX836, NP-Based Universal Influenza Vaccine Candidate, with Conventional HA-Based Influenza Vaccine: Results of Phase 2a Clinical Trial ».  Florence Nicolas, Chief Development Officer and Co-founder of Osivax, to provide additional data …

Osivax Announces Publication in The Lancet Infectious Diseases of Phase 2a Data for Broad-Spectrum Influenza Vaccine Candidate, OVX836

Osivax Announces Publication in The Lancet Infectious Diseases of Phase 2a Data for Broad-Spectrum Influenza Vaccine Candidate, OVX836 OVX836 demonstrated positive safety and immunogenicity data across three dose levels A notable signal of protection of 84% was observed against symptomatic influenza infection Lyon, France – July 28, 2023 – Osivax, a a biopharmaceutical company developing vaccines to provide …